Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Johnson & Johnson Falls Premarket; Moderna and Altimeter Rise

Published 04/13/2021, 08:19 AM
Updated 04/13/2021, 08:20 AM
© Reuters.

By Peter Nurse 

Investing.com -- Stocks in focus in premarket trade on Tuesday, April 13th. Please refresh for updates.

  • Johnson & Johnson (NYSE:JNJ) stock fell 2.3% after U.S. medical authorities called for a pause in the use of the drugmaker’s Covid-19 vaccine over blood clotting issues.

  • Altimeter Growth Corp (NASDAQ:AGC) stock rose 5.1% with the SPAC set to take Singapore-based Grab Holdings public in the U.S. The deal has been valued at almost $40 billion, the largest ever deal involving a SPAC.

  • Moderna (NASDAQ:MRNA) stock rose 7.7%, benefiting from J&J’s woes, which give it a chance to grab share in the key U.S. market. The drugmaker’s Covid-19 vaccine was rolled out for use in England earlier Tuesday. 

  • FedEx (NYSE:FDX) stock rose 1% after the investment bank KeyBanc Capital Markets upgraded its stance on the delivery giant to ‘overweight’ from ‘sector weight’, saying it can still grow numbers even as the market reopens. 

  • Alibaba (NYSE:BABA) ADR fell 0.9% after regulators in China ordered the e-commerce giant’s financial technology affiliate Ant Group to revamp its business.

  • American Airlines (NASDAQ:AAL) stock fell 3.4%, United Airlines (NASDAQ:UAL) stock dropped 3.1%, Royal Caribbean (NYSE:RCL) stock fell 2.9% and Carnival (NYSE:CUK) stock fell 2.8% as the J&J vaccine news hits stocks associated with the reopening, including the airlines and cruise companies.

  • Bristol-Myers Squibb (NYSE:BMY) stock rose 0.7% after Truist Securities upgraded its stance on the pharmaceutical company to ‘buy’ from ‘hold’, citing the company’s strong drug pipeline.

  • Credit Suisse (SIX:CSGN) stock fell 0.9% with the Swiss banking giant likely to see changes to its board. Proxy adviser Glass Lewis urged the bank’s shareholders to oppose Andreas Gottschling's re-election, on grounds that as risk committee chairman he should be held accountable for losses generated by its dealings with Greensill Bank and Archegos Capital Management.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

do something about the spam in the comments you useless bastards. did that get your attention?
Hey Dave! They certainly have no problem censoring me when I have a touchy subject to discuss.
spam
First talcum powder. Now this. Keep advertising your a caring company lol
I go the J and J shot 3 weeks ago and I have been sick ever since
RIP anyone who trusted the warp speed blood clotting vaccine for a mild coronavirus with a 99% survival rate
Please do mention the percentage of people getting blood clot after taking J&J vaccine.
To be fair, they rarely mention the survival rate of healthy people who get covid.
 they did in a separate article
I love it when a plan to correct the markets is in play now... Lol
Lol whats your name....how long have you been trading.
J&J returns our moneys
I love it when a plan to correct the markets is in play now... Lol
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.